ProfileGDS5678 / 1435064_a_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 53% 52% 52% 50% 52% 53% 54% 51% 52% 52% 52% 52% 52% 52% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 13.3404253
GSM967853U87-EV human glioblastoma xenograft - Control 23.2675452
GSM967854U87-EV human glioblastoma xenograft - Control 33.2584852
GSM967855U87-EV human glioblastoma xenograft - Control 43.1283950
GSM967856U87-EV human glioblastoma xenograft - Control 53.2091352
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 13.3978853
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 23.4328154
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 33.231351
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 43.2307752
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 13.2334852
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 23.2512552
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 33.2277952
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 43.2729252
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 53.244952